Opioid-Based Analgesia and Cancer Progression: A Mere Experimental Speculation?

Mirko Barone^1#, Regina Frontera^2,3#, Rita Vaia Liouras^2,3#, Massimo Ippoliti¹, Ivan Dell’Atti², Luigi Vetrugno^2,3, Salvatore Maurizio Maggiore^2,3, Felice Mucilli^1,3

Show Less

¹ Department of General and Thoracic Surgery, “SS. Annunziata” University Hospital, Chieti, Italy

² Department of Anaesthesiology and Intensive Care Medicine, “SS. Annunziata” University Hospital, Chieti, Italy

³ “G. d’Annunzio” University, Chieti – Pescara, Italy

EJMO 2023, 7(4), 413–414; https://doi.org/10.14744/ejmo.2023.56093

Submitted: 11 August 2023 | Accepted: 19 November 2023 | Published: 29 December 2023

© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

Conflict of interest

None declared.

References

1. Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: Delivering safe, affordable, and timely cancer surgery. Lancet Oncol 2015;16:1193−224.
2. Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011;30:225−38.
3. Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, et al. Morphine-induced epidermal growth factor path-way activation in non-small cell lung cancer. Anesth Analg 2011;113:1353−64.
4. Yamamizu K, Hamada Y, Narita M. κ Opioid receptor ligands regulate angiogenesis in development and in tumours. Br J Pharmacol 2015;172:268−76.
5. Ma M, Wang X, Liu N, Shan F, Feng Y. Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway. Int Immunopharmacol 2020;83:106388.
6. Du KN, Feng L, Newhouse A, Mehta J, Lasala J, Mena GE, et al. Effects of intraoperative opioid use on recurrencefree and overall survival in patients with esophageal adenocarcinoma and squamous cell carcinoma. Anesth Analg 2018;127:210−6.
7. Belltall A, Mazzinari G, Garrido-Cano I, Giner F, Marí AM, Eroles P, et al. Opioid receptor expression in colorectal cancer: A nested matched case-control study. Front Oncol 2022;12:801714.
8. Cata JP, Zafereo M, Villarreal J, Unruh BD, Truong A, Truong DT, et al. Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: A retrospective study. J Clin Anesth 2015;27:672−9.
9. Patino MA, Ramirez RE, Perez CA, Feng L, Kataria P, Myers J, et al. The impact of intraoperative opioid use on survival after oral cancer surgery. Oral Oncol 2017;74:1−7.
10. Oh TK, Jeon JH, Lee JM, Kim MS, Kim JH, Cho H, et al. Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery. PLoS One 2017;12:e0181672.
11. Novy DM, Nelson DV, Koyyalagunta D, Cata JP, Gupta P, Gupta K. Pain, opioid therapy, and survival: A needed discussion. Pain 2020;161:496−501.
12. Chong D, Shao L, Yang Y, Wang R, Yang C, Zhang B. Correlations of cancer pain degree with levels of β-EP, CGRP and PGE2 and the effects of oxycontin on them. J BUON 2018;23:1552−7.

Previous article in this issue

Next article in this issue

Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing